Daraxonrasib Doubles Second-Line Overall Survival in Metastatic Pancreatic Cancer Trial
The phase III RASolute-302 trial demonstrated that the pan-RAS inhibitor daraxonrasib doubled median overall survival compared to chemotherapy in second-line ...
The phase III RASolute-302 trial demonstrated that the pan-RAS inhibitor daraxonrasib doubled median overall survival compared to chemotherapy in second-line ...
A phase I/II clinical trial found that combining daraxonrasib with standard chemotherapy induced substantial tumour shrinkage and prolonged disease control ...
A major scientific review highlights how novel targeted therapies, spearheaded by the pan-RAS inhibitor daraxonrasib, are dramatically extending survival and ...
A comprehensive review outlines how tissue context, co-mutations, and wild-type signaling cross-talk govern therapeutic durability and resistance across oncogenic RAS-driven ...
A partitioned survival model indicates that daraxonrasib improves survival outcomes in metastatic pancreatic ductal adenocarcinoma but requires major price reductions ...
A phase 3 trial of the pan-RAS inhibitor daraxonrasib doubled median overall survival in previously treated metastatic pancreatic cancer, prompting ...
A review finds peripheral oedema and hypertension documented with daraxonrasib, but no published cardiac endpoint data at Phase 3 scale.
A new review details how the pan-RAS inhibitor daraxonrasib doubled overall survival in a phase III pancreatic cancer trial and ...
Preclinical work shows the pan-RAS inhibitor RMC-6236 triggers adaptive EGFR feedback in KRAS-mutant cholangiocarcinoma cells, and pairing it with cetuximab ...
A subgroup analysis of the phase 3 RASolute 302 trial presented at ESMO found the targeted RAS inhibitor daraxonrasib extended ...
Sylvester Comprehensive Cancer Center researchers report an FDA approval for a pancreatic cancer pill that nearly doubled survival, alongside new ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.